Published in J Infect Dis on December 01, 1987
Biology of Giardia lamblia. Clin Microbiol Rev (2001) 5.35
Treatment of giardiasis. Clin Microbiol Rev (2001) 2.66
Giardiasis. Clin Microbiol Rev (1992) 2.44
The biology of Giardia spp. Microbiol Rev (1991) 2.28
Draft genome sequencing of giardia intestinalis assemblage B isolate GS: is human giardiasis caused by two different species? PLoS Pathog (2009) 1.97
Persistent G. lamblia impairs growth in a murine malnutrition model. J Clin Invest (2013) 1.81
Effect of chronic Giardia lamblia infection on epithelial transport and barrier function in human duodenum. Gut (2006) 1.60
Giardia--diagnosis, clinical course and epidemiology. A review. Epidemiol Infect (1992) 1.59
Behind the smile: cell biology and disease mechanisms of Giardia species. Nat Rev Microbiol (2010) 1.55
Immune response to Giardia duodenalis. Clin Microbiol Rev (2000) 1.54
Central importance of immunoglobulin A in host defense against Giardia spp. Infect Immun (2002) 1.54
A systematic review and meta-analysis of the association between Giardia lamblia and endemic pediatric diarrhea in developing countries. Clin Infect Dis (2012) 1.35
Sensitivity of microscopy versus enzyme immunoassay in the laboratory diagnosis of giardiasis. Eur J Clin Microbiol Infect Dis (1997) 1.35
Isolate and epitope variability in susceptibility of Giardia lamblia to intestinal proteases. Infect Immun (1991) 1.22
A novel, multi-parallel, real-time polymerase chain reaction approach for eight gastrointestinal parasites provides improved diagnostic capabilities to resource-limited at-risk populations. Am J Trop Med Hyg (2013) 1.19
Antigenic variation in Giardia lamblia and the host's immune response. Philos Trans R Soc Lond B Biol Sci (1997) 1.17
Intestinal mucosal responses to microbial infection. Springer Semin Immunopathol (2005) 1.10
Factors that explain excretion of enteric pathogens by persons without diarrhea. Clin Infect Dis (2012) 1.09
Disruption of antigenic variation is crucial for effective parasite vaccine. Nat Med (2010) 1.09
Variant surface antigens of Giardia lamblia are associated with the presence of a thick cell coat: thin section and label fracture immunocytochemistry survey. Infect Immun (1991) 1.08
High-throughput Giardia lamblia viability assay using bioluminescent ATP content measurements. Antimicrob Agents Chemother (2010) 1.05
Cross-species transmission of Giardia spp.: inoculation of beavers and muskrats with cysts of human, beaver, mouse, and muskrat origin. Appl Environ Microbiol (1988) 1.01
Antigiardial activity of Ocimum basilicum essential oil. Parasitol Res (2007) 0.98
Α1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine model. Vaccine (2011) 0.98
Adaptive immunity-dependent intestinal hypermotility contributes to host defense against Giardia spp. Infect Immun (2006) 0.96
Comparison of levels of inactivation of two isolates of Giardia lamblia cysts by UV light. Appl Environ Microbiol (2007) 0.95
Genetic homogeneity of axenic isolates of Giardia intestinalis derived from acute and chronically infected individuals in Mexico. Parasitol Res (2003) 0.95
Comparison of antibody and cytokine responses to primary Giardia muris infection in H-2 congenic strains of mice. Infect Immun (1996) 0.94
Investigation of human giardiasis by karyotype analysis. J Clin Invest (1992) 0.94
Multiplex assay detection of immunoglobulin G antibodies that recognize Giardia intestinalis and Cryptosporidium parvum antigens. Clin Vaccine Immunol (2010) 0.93
Genome sequencing of Giardia lamblia genotypes A2 and B isolates (DH and GS) and comparative analysis with the genomes of genotypes A1 and E (WB and Pig). Genome Biol Evol (2013) 0.93
Structure of a frequently rearranged rRNA-encoding chromosome in Giardia lamblia. Nucleic Acids Res (1995) 0.91
Gastric giardiasis. J Clin Pathol (1992) 0.90
Inhibition of Giardia lamblia excystation by antibodies against cyst walls and by wheat germ agglutinin. Infect Immun (1996) 0.90
Advances in understanding Giardia: determinants and mechanisms of chronic sequelae. F1000Prime Rep (2015) 0.90
Human Memory CD4+ T Cell Immune Responses against Giardia lamblia. Clin Vaccine Immunol (2015) 0.88
Is human giardiasis caused by two different Giardia species? Gut Microbes (2011) 0.88
Human secretory and serum antibodies recognize environmentally induced antigens of Giardia lamblia. Infect Immun (1992) 0.87
Antigenic switching of TSA 417, a trophozoite variable surface protein, following completion of the life cycle of Giardia lamblia. Infect Immun (1993) 0.87
Allele-specific expression of a variant-specific surface protein (VSP) of Giardia lamblia. Nucleic Acids Res (1994) 0.86
Elevated levels of immunoglobulin A to Giardia lamblia during a waterborne outbreak of gastroenteritis. J Clin Microbiol (1989) 0.86
Laboratory diagnosis for Giardia lamblia infection: A comparison of microscopy, coprodiagnosis and serology. Can J Infect Dis (1997) 0.86
Unraveling how Giardia infections cause disease. J Clin Invest (2013) 0.85
Serum antibodies to Giardia lamblia by age in populations in Colorado and Thailand. West J Med (1990) 0.84
Biological significance of Giardia-specific antibodies. West J Med (1990) 0.82
Secretory immune response to membrane antigens during Giardia lamblia infection in humans. Infect Immun (1998) 0.81
Disruptions of Host Immunity and Inflammation by Giardia Duodenalis: Potential Consequences for Co-Infections in the Gastro-Intestinal Tract. Pathogens (2015) 0.80
Drug Development Against the Major Diarrhea-Causing Parasites of the Small Intestine, Cryptosporidium and Giardia. Front Microbiol (2015) 0.80
Inferences drawn from a risk assessment compared directly with a randomized trial of a home drinking water intervention. Environ Health Perspect (2006) 0.78
Rapid detection and enumeration of Giardia lamblia cysts in water samples by immunomagnetic separation and flow cytometric analysis. Appl Environ Microbiol (2011) 0.78
Effects of dietary zinc manipulation on growth performance, zinc status and immune response during Giardia lamblia infection: a study in CD-1 mice. Nutrients (2013) 0.76
Individual subject meta-analysis of parameters for Giardia duodenalis shedding in animal experimental models. Biomed Res Int (2014) 0.76
Modeling long-term host cell-Giardia lamblia interactions in an in vitro co-culture system. PLoS One (2013) 0.76
Giardia: a pathogen or commensal for children in high-prevalence settings? Curr Opin Infect Dis (2016) 0.75
Giardiasis outbreaks in the United States, 1971-2011. Epidemiol Infect (2016) 0.75
Giardiasis of the stomach. Postgrad Med J (1994) 0.75
Giardia and Vilém Dušan Lambl. PLoS Negl Trop Dis (2014) 0.75
A novel in vitro image-based assay identifies new drug leads for giardiasis. Int J Parasitol Drugs Drug Resist (2017) 0.75
Human secretory immune response to fatty acid-binding protein fraction from Giardia lamblia. Infect Immun (2002) 0.75
Cryptosporidium and Giardia in Africa: current and future challenges. Parasit Vectors (2017) 0.75
Use of Pathogen-Specific Antibody Biomarkers to Estimate Waterborne Infections in Population-Based Settings. Curr Environ Health Rep (2016) 0.75
Attaching and effacing activities of rabbit and human enteropathogenic Escherichia coli in pig and rabbit intestines. Infect Immun (1983) 12.81
Cholera. Clin Microbiol Rev (1995) 12.33
Escherichia coli that cause diarrhea: enterotoxigenic, enteropathogenic, enteroinvasive, enterohemorrhagic, and enteroadherent. J Infect Dis (1987) 12.26
Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. Lancet (1978) 10.29
Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med (1988) 9.19
The diarrheal response of humans to some classic serotypes of enteropathogenic Escherichia coli is dependent on a plasmid encoding an enteroadhesiveness factor. J Infect Dis (1985) 9.18
Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ (1999) 8.93
A DNA probe to identify enterohemorrhagic Escherichia coli of O157:H7 and other serotypes that cause hemorrhagic colitis and hemolytic uremic syndrome. J Infect Dis (1987) 8.19
Detection of an adherence factor of enteropathogenic Escherichia coli with a DNA probe. J Infect Dis (1985) 7.78
New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev (1983) 7.16
Patterns of adherence of diarrheagenic Escherichia coli to HEp-2 cells. Pediatr Infect Dis J (1987) 7.15
Experimental Campylobacter jejuni infection in humans. J Infect Dis (1988) 7.05
A critical appraisal of 98.6 degrees F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. JAMA (1992) 6.88
Plasmid-mediated adhesion in enteropathogenic Escherichia coli. J Pediatr Gastroenterol Nutr (1983) 6.59
Enteropathogenic Escherichia coli of classic serotypes associated with infant diarrhea: epidemiology and pathogenesis. Epidemiol Rev (1984) 5.98
Plasmid-mediated factors conferring diffuse and localized adherence of enteropathogenic Escherichia coli. Infect Immun (1985) 5.42
Characterization of enteroadherent-aggregative Escherichia coli, a putative agent of diarrheal disease. J Infect Dis (1988) 5.30
Relative efficacy of blood, urine, rectal swab, bone-marrow, and rose-spot cultures for recovery of Salmonella typhi in typhoid fever. Lancet (1975) 4.85
Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection. J Clin Invest (1993) 4.53
Enteroaggregative Escherichia coli associated with persistent diarrhea in a cohort of rural children in India. J Infect Dis (1989) 4.52
A sensitive and specific DNA probe to identify enteroaggregative Escherichia coli, a recently discovered diarrheal pathogen. J Infect Dis (1990) 4.43
Summary of an international workshop on typhoid fever. Rev Infect Dis (1986) 4.21
Role of a 60-megadalton plasmid and Shiga-like toxins in the pathogenesis of infection caused by enterohemorrhagic Escherichia coli O157:H7 in gnotobiotic piglets. Infect Immun (1987) 3.96
A plasmid of enterohemorrhagic Escherichia coli O157:H7 is required for expression of a new fimbrial antigen and for adhesion to epithelial cells. Infect Immun (1987) 3.76
Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis (1989) 3.71
Coli surface antigens 1 and 3 of colonization factor antigen II-positive enterotoxigenic Escherichia coli: morphology, purification, and immune responses in humans. Infect Immun (1984) 3.63
Duration of infection-derived immunity to cholera. J Infect Dis (1981) 3.60
Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature (1987) 3.51
Pathogenesis of Shigella dysenteriae 1 (Shiga) dysentery. J Infect Dis (1973) 3.45
Aggregative adherence fimbriae I of enteroaggregative Escherichia coli mediate adherence to HEp-2 cells and hemagglutination of human erythrocytes. Infect Immun (1992) 3.30
Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. J Infect Dis (1982) 3.28
Heterogeneity of enteroaggregative Escherichia coli virulence demonstrated in volunteers. J Infect Dis (1995) 3.14
Recombinant nontoxinogenic Vibrio cholerae strains as attenuated cholera vaccine candidates. Nature (1984) 3.08
Diagnostic value of the Widal test in areas endemic for typhoid fever. Am J Trop Med Hyg (1978) 3.06
Environmental and human isolates of Vibrio cholerae and Vibrio parahaemolyticus produce a Shigella dysenteriae 1 (Shiga)-like cytotoxin. Lancet (1984) 3.05
Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. J Clin Invest (1987) 3.03
Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens. Lancet (1998) 2.98
Adsorption and growth of Vibrio cholerae on chitin. Infect Immun (1979) 2.90
From the National Institute of Allergy and Infectious Diseases. Summary of a workshop on enteropathogenic Escherichia coli. J Infect Dis (1983) 2.71
Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: application in serodiagnosis and seroepidemiology. J Clin Microbiol (1985) 2.66
Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine. J Infect Dis (1977) 2.57
Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J Infect Dis (1997) 2.55
Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans R Soc Trop Med Hyg (1979) 2.51
Diarrhea caused by Escherichia coli that produce only heat-stable enterotoxin. Infect Immun (1977) 2.49
Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine. Infect Immun (1984) 2.48
Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains. Infect Immun (1995) 2.45
Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect Immun (1997) 2.44
Comparison of two assay methods for patterns of adherence to HEp-2 cells of Escherichia coli from patients with diarrhea. J Clin Microbiol (1990) 2.43
Evaluation of the human immune response to outer membrane proteins of Vibrio cholerae. Infect Immun (1984) 2.42
Construction of genetically defined double aro mutants of Salmonella typhi. Vaccine (1991) 2.42
Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers. Infect Immun (1980) 2.42
Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro. J Clin Invest (1995) 2.41
Enteroaggregative Escherichia coli elaborate a heat-stable enterotoxin demonstrable in an in vitro rabbit intestinal model. J Clin Invest (1991) 2.35
Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. Am J Epidemiol (1991) 2.34
Morphological studies on fimbriae expressed by Vibrio cholerae 01. Microb Pathog (1988) 2.33
Experimental non-O group 1 Vibrio cholerae gastroenteritis in humans. J Clin Invest (1990) 2.33
Reduction of transmission of shigellosis by control of houseflies (Musca domestica) Lancet (1991) 2.30
Immunity to enterotoxigenic Escherichia coli. Infect Immun (1979) 2.30
Enteroaggregative Escherichia coli heat-stable enterotoxin 1 represents another subfamily of E. coli heat-stable toxin. Proc Natl Acad Sci U S A (1993) 2.28
Hemagglutination and colonization factors in enterotoxigenic and enteropathogenic Escherichia coli that cause diarrhea. J Infect Dis (1980) 2.26
The capsule and O antigen in Vibrio cholerae O139 Bengal are associated with a genetic region not present in Vibrio cholerae O1. Infect Immun (1995) 2.25
Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers. Infect Immun (1992) 2.23
Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat Med (1998) 2.20
Typhoid fever vaccines. Vaccine (1999) 2.18
Vibrio cholerae O1 can assume a chlorine-resistant rugose survival form that is virulent for humans. J Infect Dis (1996) 2.17
Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet (1987) 2.17
Precise estimation of the numbers of chronic carriers of Salmonella typhi in Santiago, Chile, an endemic area. J Infect Dis (1982) 2.14
The pathogenicity of nonenterotoxigenic Vibrio cholerae serogroup O1 biotype El Tor isolated from sewage water in Brazil. J Infect Dis (1982) 2.13
Temperature-sensitive mutants of influenza A virus. XII. Safety, antigenicity, transmissibility, and efficacy of influenza A/Udorn/72-ts-1[E] recombinant viruses in human adults. J Infect Dis (1976) 2.12
Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge. J Infect Dis (1995) 2.10
Human infection with Ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin B subunit following vaccination with the live oral cholera vaccine CVD 103-HgR. Infect Immun (2001) 2.09
Viable but non-culturable Vibrio cholerae O1 revert to a cultivable state in the human intestine. World J Microbiol Biotechnol (1996) 2.05
Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. N Engl J Med (1988) 2.04
Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi. J Infect Dis (1994) 2.03
Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis (2000) 2.02
Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus. Infect Immun (1983) 2.01
Oral administration of human rotavirus to volunteers: induction of illness and correlates of resistance. J Infect Dis (1983) 1.94
Haemophilus influenzae can use human transferrin as a sole source for required iron. Infect Immun (1985) 1.94
Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J Infect Dis (1992) 1.94
Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae. J Infect Dis (1993) 1.93
Investigation of the roles of toxin-coregulated pili and mannose-sensitive hemagglutinin pili in the pathogenesis of Vibrio cholerae O139 infection. Infect Immun (1998) 1.90
Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. J Infect Dis (1987) 1.90
Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect Immun (1987) 1.89
Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults. Vaccine (1990) 1.87
Purification, morphology, and genetics of a new fimbrial putative colonization factor of enterotoxigenic Escherichia coli O159:H4. Infect Immun (1987) 1.86
Studies with enteroaggregative Escherichia coli in the gnotobiotic piglet gastroenteritis model. Infect Immun (1992) 1.84
Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR. J Infect Dis (2000) 1.82
Vi serology in detection of chronic Salmonella typhi carriers in an endemic area. Lancet (1983) 1.78
A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine (1995) 1.74
Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b. Pediatr Infect Dis J (1999) 1.73
Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain. Vaccine (1992) 1.69
Longus: a long pilus ultrastructure produced by human enterotoxigenic Escherichia coli. Mol Microbiol (1994) 1.69
Enteroaggregative Escherichia coli heat-stable enterotoxin is not restricted to enteroaggregative E. coli. J Infect Dis (1996) 1.69
Molecular techniques in the study of Salmonella typhi in epidemiologic studies in endemic areas: comparison with Vi phage typing. Am J Trop Med Hyg (1986) 1.68